486 related articles for article (PubMed ID: 24666664)
1. Aberrant drug-related behavior observed during a 12-week open-label extension period of a study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain.
Passik SD; Narayana A; Yang R
Pain Med; 2014 Aug; 15(8):1365-72. PubMed ID: 24666664
[TBL] [Abstract][Full Text] [Related]
2. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes.
Webster LR; Slevin KA; Narayana A; Earl CQ; Yang R
Pain Med; 2013 Sep; 14(9):1332-45. PubMed ID: 23855816
[TBL] [Abstract][Full Text] [Related]
3. Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain.
Passik SD; Messina J; Golsorkhi A; Xie F
J Pain Symptom Manage; 2011 Jan; 41(1):116-25. PubMed ID: 20580202
[TBL] [Abstract][Full Text] [Related]
4. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Simpson DM; Messina J; Xie F; Hale M
Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain.
Ashburn MA; Slevin KA; Messina J; Xie F
Anesth Analg; 2011 Mar; 112(3):693-702. PubMed ID: 21304148
[TBL] [Abstract][Full Text] [Related]
6. Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management.
Fine PG; Narayana A; Passik SD
Pain Med; 2010 Jul; 11(7):1024-36. PubMed ID: 20642730
[TBL] [Abstract][Full Text] [Related]
7. Effect of fentanyl buccal tablet on pain-related anxiety: a 4-week open-label study among opioid-tolerant patients with chronic and breakthrough pain.
Webster LR; Messina J; Xie F; Nalamachu S
J Opioid Manag; 2011; 7(4):297-308. PubMed ID: 21957829
[TBL] [Abstract][Full Text] [Related]
8. Fentanyl buccal tablet.
Messina J; Darwish M; Fine PG
Drugs Today (Barc); 2008 Jan; 44(1):41-54. PubMed ID: 18301803
[TBL] [Abstract][Full Text] [Related]
9. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study.
Portenoy RK; Messina J; Xie F; Peppin J
Curr Med Res Opin; 2007 Jan; 23(1):223-33. PubMed ID: 17207304
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients.
Kosugi T; Hamada S; Takigawa C; Shinozaki K; Kunikane H; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
J Pain Symptom Manage; 2014 Jun; 47(6):990-1000. PubMed ID: 24099893
[TBL] [Abstract][Full Text] [Related]
11. Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain.
Mercadante S
Expert Rev Clin Pharmacol; 2015 Jan; 8(1):9-13. PubMed ID: 25359295
[TBL] [Abstract][Full Text] [Related]
12. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer.
Portenoy RK; Taylor D; Messina J; Tremmel L
Clin J Pain; 2006; 22(9):805-11. PubMed ID: 17057563
[TBL] [Abstract][Full Text] [Related]
13. Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese cancer patients with detailed evaluation.
Takigawa C; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
Jpn J Clin Oncol; 2015 Jan; 45(1):67-74. PubMed ID: 25381384
[TBL] [Abstract][Full Text] [Related]
14. A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain.
Farrar JT; Messina J; Xie F; Portenoy RK
Pain Med; 2010 Sep; 11(9):1313-27. PubMed ID: 20807345
[TBL] [Abstract][Full Text] [Related]
15. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study.
Weinstein SM; Messina J; Xie F
Cancer; 2009 Jun; 115(11):2571-9. PubMed ID: 19373888
[TBL] [Abstract][Full Text] [Related]
16. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
[TBL] [Abstract][Full Text] [Related]
17. Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomized, Crossover, Comparison Study.
Mercadante S; Adile C; Cuomo A; Aielli F; Cortegiani A; Casuccio A; Porzio G
J Pain Symptom Manage; 2015 Nov; 50(5):579-86. PubMed ID: 26303188
[TBL] [Abstract][Full Text] [Related]
18. Pan-European, open-label dose titration study of fentanyl buccal tablet in patients with breakthrough cancer pain.
Kleeberg UR; Davies A; Jarosz J; Mercadante S; Poulain P; O'Brien T; Schneid H; Kress HG
Eur J Pain; 2015 Apr; 19(4):528-37. PubMed ID: 25181451
[TBL] [Abstract][Full Text] [Related]
19. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain.
Slatkin NE; Xie F; Messina J; Segal TJ
J Support Oncol; 2007; 5(7):327-34. PubMed ID: 17708123
[TBL] [Abstract][Full Text] [Related]
20. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
Mercadante S; Ferrera P; Adile C; Casuccio A
J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
